Spondylolisthesis, grade 3

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%